Both Rapid and Sustained Pain Relief for up to 48 Hours Conference call to be Held Today at 8:30 a.m. ET MOUNTAIN VIEW, Calif., May 26 (HSMN NewsFeed) — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today that the efficacy portion of its fir…
Biopharmaceuticals
MAP Pharmaceuticals, LEVADEX, MAP0004, migraine

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints”
Leave a Comment